Despite being among the most common oncogenes in human
cancer, to date, there are no effective clinical options for inhibiting KRAS activity. We investigated whether systemically delivered KRAS siRNAs have therapeutic potential in KRAS-mutated
cancer models. We identified KRAS
siRNA sequences with notable potency in knocking down KRAS expression. Using lung and
colon adenocarcinoma cell lines, we assessed antiproliferative effects of KRAS silencing in vitro. For in vivo experiments, we used a nanoliposomal delivery platform,
DOPC, for systemic delivery of siRNAs. Various lung and
colon cancer models were used to determine efficacy of systemic KRAS
siRNA based on
tumor growth, development of
metastasis, and downstream signaling. KRAS
siRNA sequences induced >90% knockdown of KRAS expression, significantly reducing viability in mutant cell lines. In the
lung cancer model, KRAS
siRNA treatment demonstrated significant reductions in primary
tumor growth and distant metastatic disease, while the addition of CDDP was not additive. Significant reductions in Ki-67 indices were seen in all treatment groups, whereas significant increases in
caspase-3 activity were only seen in the CDDP treatment groups. In the
colon cancer model, KRAS
siRNA reduced
tumor KRAS and pERK expression. KRAS siRNAs significantly reduced HCP1 subcutaneous
tumor growth, as well as outgrowth of liver
metastases. Our studies demonstrate a proof-of-concept approach to therapeutic KRAS targeting using nanoparticle delivery of
siRNA. This study highlights the potential translational impact of therapeutic RNA interference, which may have broad applications in oncology, especially for traditional "undruggable" targets.